Screening Method in Sacral Neuromodulation

Sponsor
Maastricht University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT01130415
Collaborator
Scientific Foundation Urology Maastricht (Other)
64
1
86
0.7

Study Details

Study Description

Brief Summary

The purpose of this study was to evaluate whether there is a difference in long-term outcome between patients screened with the percutaneous nerve evaluation (PNE) and first stage tined lead procedure (TLP).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Purpose: To evaluate if there is a difference in long-term outcome of sacral neuromodulation (SNM) between patients screened with the percutaneous nerve evaluation (PNE) and first stage tined lead procedure (TLP). Furthermore, we wanted to evaluate the outcome in patients who only responded to screening with TLP after failure of initial PNE.

    Materials and methods: We evaluated all patients screened for eligibility to receive SNM treatment since the introduction of the tined lead technique in our centre in 2002. In May 2009, all implanted patients were asked to keep a voiding diary to record the effect of SNM on urinary symptoms. Success was defined as more than 50% improvement in at least one of the relevant voiding diary parameters compared to baseline. Chi square analysis was used to evaluate differences in long-term outcome for the separate screening methods.

    Results: In total, 92 patients were screened for SNM. Of the 76 patients who were screened with PNE, 35 (46%) met the criteria for permanent implantation, whereas 11 of the 16 patients (69%) who underwent direct screening with TLP had permanent stimulators placed. Of the 41 patients who failed PNE and subsequently underwent screening with TLP, 18 (44%) were implanted with an INS after showing a successful response. The mean follow-up was 53 months (range 35-77 months) at the time of voiding diary analysis. Statistical analysis showed no difference between type of screening and long-term success (p=0.94).

    Conclusion: Although first stage TLP is a more reliable screening tool than PNE, the long-term success rate does not seem to be dependent on the screening method. Furthermore, patients who initially failed PNE but responded to prolonged screening with TLP, appear to be at least as successful in the long-term as patients who directly responded to PNE or TLP.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    64 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Is the Method of Screening in Sacral Neuromodulation a Prognostic Factor for Long-term Success?
    Study Start Date :
    May 1, 2002
    Actual Primary Completion Date :
    May 1, 2009
    Actual Study Completion Date :
    Jul 1, 2009

    Arms and Interventions

    Arm Intervention/Treatment
    Patients treated with sacral neuromodulation

    Outcome Measures

    Primary Outcome Measures

    1. long-term success measured with voiding diaries [5 years]

      Successful treatment was defined as more than 50 percent improvement in the key voiding diary variables compared to baseline.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients who have been treated for overactive bladder syndrome or chronic non-obstructive urinary retention with sacral neuromodulation by using the tined lead
    Exclusion Criteria:
    • patients with bilateral implantation of a tined lead

    • patients who have been treated with sacral neuromodulation for pelvic pain

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Maastricht University Medical Centre Maastricht Limburg Netherlands P.O. box 5800, 6202 AZ

    Sponsors and Collaborators

    • Maastricht University Medical Center
    • Scientific Foundation Urology Maastricht

    Investigators

    • Study Director: Philip van Kerrebroeck, Prof, Maastricht University Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01130415
    Other Study ID Numbers:
    • 1234
    First Posted:
    May 26, 2010
    Last Update Posted:
    May 26, 2010
    Last Verified:
    May 1, 2010

    Study Results

    No Results Posted as of May 26, 2010